First-in-human Study of Naporafenib (LXH254) with or Without Spartalizumab in Adult Patients with Advanced Solid Tumors Harboring MAPK Signaling Pathway Alterations

Janku, Filip, Kim, Tae Min, Iyer, Gopakumar, Spreafico, Anna, Elez, Elena, de Jonge, Maja, Yamamoto, Noboru, van der Wekken, Anthonie J., Ascierto, Paolo Antonio, Maur, Michela, Marmé, Frederik, Kiladjian, Jean-Jacques, Basu, Sumit, Baffert, Fabienne, Buigues, Amparo, Chen, Chi, Cooke, Vesselina, Giorgetti, Elisa, Jaeyeon, McCarthy, Fiona, Moschetta, Michele, Dummer, Reinhard